Acute lymphoblastic leukemia of adults – a case of prolonged hip pain diagnostics with a surprising conclusion: case report

Česká verze

Authors: Štěpán Hrabovský ¹; František Folber ¹; Barbora Jurová ²; Zdeněk Řehák ³; Michael Doubek ^1,4
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice ¹; Klinika radiologie a nukleární medicíny LF MU a FN Brno, pracoviště Bohunice ²; Oddělení nukleární medicíny, PET centrum, RECAMO, MOÚ, Brno ³; Středoevropský technologický institut (CEITEC), Brno ⁴
Published in the journal: Vnitř Lék 2017; 63(5): 348-353
Category: Kazuistiky

Summary

Though acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood age, it is a rare diagnosis in adults. This disease often manifests with common and nonspecific symptoms, so it can easily escape an early diagnostics without a proper blood count examination. We present a case of an adult ALL patient suffering only from severe hips and thighs pain, without any significant blood count abnormities leading to the diagnostics. In the second part of the article, we summarize current highlights regarding this disease.

Key words:
acute lymphoblastic leukemia – adult – biological treatment – bone pain – CAR T-cells – osteolysis – symptoms

Zdroje

1. Hann IM, Gupta S, Palmer MK et al. The prognostic significance of radiological and symptomatic bone involvement in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1979; 6(1): 51–55.

2. Ribeiro RC, Pui CH, Schell MJ. Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer 1988; 61(3): 589–592.

3. Jonsson OG, Sartain P, Ducore JM et al. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. J Pediatr 1990; 117(2 Pt 1): 233–237.

4. Müller HL, Horwitz AE, Kühl J. Acute lymphoblastic leukemia with severe skeletal involvement: a subset of childhood leukemia with a good prognosis. Pediatr Hematol Oncol 1998; 15(2): 121–133.

5. Sinigaglia R, Gigante C, Bisinella G et al. Musculoskeletal manifestations in pediatric acute leukemia. J Pediatr Orthop 2008; 28(7): 20–28. Dostupné z DOI: <http://dx.doi.org/10.1097/BPO.0b013e318186eb99>.

6. Riccio I, Marcarelli M, Del Regno N et al. Musculoskeletal problems in pediatric acute leukemia. J Pediatr Orthop B 2013; 22(3): 264–269. Dostupné z DOI: <http://dx.doi.org/10.1097/BPB.0b013e32835d731c>.

7. Azorová L, Folber F. Epidemiológia akutnej lymfoblastickej leukémie dospelých v Juhomoravskom kraji. LF MU: Brno 2016. Samostatná studentská práce.

8. Adamovičová D, Bližňáková M, Folber F. Laboratorní parametry u nově diagnostikované akutní lymfoblastické leukemie dospělých. LF MU: Brno 2016. Samostatná studentská práce.

9. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391–2405. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2016–03–643544>.

10. Šálek C, Folber F, Froňková E et al. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol 2016; 96(3): 276–284. Dostupné z DOI: <http://dx.doi.org/10.1111/ejh.12587>.

11. Brüggemann M, Raff T, Flohr T et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107(3): 1116–1123.

12. Gökbuget N, Kneba M, Raff T et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120(9): 1868–1876.

13. Cole CH. Lessons from 50 years of curing childhood leukaemia. J Paediatr Child Health 2015; 51(1): 78–81. Dostupné z DOI: <http://dx.doi.org/10.1111/jpc.12803>.

14. O‘Brien S, Thomas DA, Ravandi F et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008; 113(8): 2097–2101. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.23819>.

15. Šálek C, Šponerová D, Soukupová Maaloufová J. Akutní lymfoblastová leukemie: historie a současnost. Vnitř Lék 2012; 58(Suppl 2): 20–26.

16. Kantarjian H, Stein A, Gökbuget N et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017; 376(9): 836–847. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1609783>.

17. Kantarjian HM, DeAngelo DJ, Stelljes M et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375(8): 740–753. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1509277>.

18. Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL. ClinicalTrials.gov Identifier: NCT02848911. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02848911>.

19. Maude SL, Frey N, Shaw PA et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med 2014; 371(16): 1507–1517. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1407222>.

20. Davila ML, Riviere I, Wang X et al. Efficacy and Toxicity Management of 19–28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med 2014; 6(224): 224ra25. Dostupné z DOI: <http://dx.doi.org/10.1126/scitranslmed.3008226>.

21. Chang LJ, Dong L, Liu YC et al. Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia – Three-Year Follow-up of a Multicenter Phase I/II Study. Blood 2016; 128: 587. Dostupné z WWW: <http://www.bloodjournal.org/content/128/22/587>.

22. Gardner R, Leger KJ, Annesley CE et al. Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management. Blood 2016; 128: 586. Dostupné z WWW: <http://www.bloodjournal.org/content/128/22/586>.